Novartis

NEW YORK (AP) - Idera Pharmaceuticals Inc. on Wednesday announced the end of a research partnership with Novartis AG, but said Merck & Co. is extending its work with Idera for another year. Novartis, a Swiss drugmaker, will end its work...

In this article: Novartis AG, Merck & Co., Cancer, Asthma, Alzheimer's disease, Allergy, Respiratory disease, Cambridge, and NEW YORK

* Gains access to 2 therapies for blood disorders, cancers * Novartis to pay Incyte $150 million upfront * Also pays $60 mln milestone at start of Phase III trial * Incyte shares rise 5.3 pct; Novartis up 0.6 pct (Adds Incyte share...

In this article: Cancer, Nasdaq, Jpmorgan, and United States

...respiratory conditions. Idera will now retain all the rights to that drug it was co-developing with Novartis, called IMO-2134. The end of the Novartis deal isn't the end of the world for Idera. It still has active collaborations with...

In this article: Merck & Co., All rights reserved, WordPress, Cancer, Asthma, Alzheimer's disease, Allergy, and Respiratory disease

.../quotes/comstock/15*!idra/quotes/nls/idra (IDRA 5.00, 0.00, 0.00%) said early Wednesday that Novartis AG /quotes/comstock/13*!nvs/quotes/nls/nvs (NVS 55.30, +0.55, +1.00%) plans to terminate the companies' collaboration agreement on Feb....

In this article: Asthma, Allergy, MarketWatch, and Boston

...construction, validation and licensing of the manufacturing facility in Holly Springs," the company said. When it gets up and going, Novartis says the Holly Springs facility will be able to make 50 million doses of seasonal flu vaccine a...

In this article: United States, HHS, Holly Springs, Sanofi, U.S. Centers for Disease Control and Prevention, MedImmune, U.S. House of Representatives, and European Union

...is declared. The sale of flu vaccines from cell cultures is not yet approved in the United States, but Novartis is allowed to produce them there. The company said its agreement with the Health Department also includes funding for the...

In this article: Novartis AG, United States, Chicago Tribune, U.S. Department of Health and Human Services, Basel, Marburg, Holly Springs, Zurich, and North Carolina

In this article: Novartis AG, North Carolina, United States, U.S. Department of Health and Human Services, Basel, Marburg, Holly Springs, Zurich, and Germany

...and the elderly. All A(H1N1) 2009 influenza study vaccines were manufactured using the Novartis established seasonal Fluvirin® manufacturing platform. Novartis has discussed these new data with the US Food and Drug Administration (FDA) and...

In this article: United States, Influenza vaccine, FDA, US Department Of Health And Human Services, Medical advice, Google map, and European Union

BASEL, Switzerland -- Pharmaceutical maker Novartis AG said Tuesday a U.S. clinical study suggests that half a dose of its swine flu vaccine may be sufficient to protect people from the virus and could allow many more to be immunized with...

In this article: Novartis AG, United States, Fluvirin, Food and Drug Administration, Basel, Europe, and Switzerland

...dose of the Novartis AG H1N1 vaccine may be enough to generate a protective immune response, the Swiss drugmaker said on Tuesday. Novartis said data from about 4,000 individuals suggested that half a dose of its U.S.-approved unadjuvanted...

In this article: FDA, U.S., CSL Limited, MedImmune, and Sanofi-Aventis